FANGDA PARTNERS 上海市方达（广州）律师事务所 关于百奥泰生物制药股份有限公司 2025 年第二次临时股东会的法律意见书 致：百奥泰生物制药股份有限公司 上海市方达（广州）律师事务所（以下简称"本所"）是具有中华人民共和国 境内法律执业资格的律师事务所。根据相关法律顾问协议，本所指派律师出席百 奥泰生物制药股份有限公司（以下简称"公司"）2025 年第二次临时股东会（以下 简称"本次股东会"），并就本次股东会的召集和召开程序、参与表决和召集会议 人员的资格、表决程序和表决结果等有关事宜出具本法律意见书。 本法律意见书依据《中华人民共和国公司法》《中华人民共和国证券法》《上 市公司股东会规则》及其他相关中华人民共和国境内已公开颁布并生效的法律、 法规、规章及规范性文件（以下合称"中国法律法规"）以及《百奥泰生物制药股 份有限公司章程》（以下称"《公司章程》"）的规定出具。 本法律意见书仅就本次股东会的召集和召开程序、出席会议人员、召集人、 表决程序是否符合相关中国法律法规及《公司章程》的规定以及表决结果是否合 法、有效发表意见，并不对任何中国法律法规以外的国家或地区的法律发表任何 意见。本法律意见 ...

本次会议是否有被否决议案：无 一、 会议召开和出席情况 2025年第二次临时股东会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 百奥泰生物制药股份有限公司 证券代码：688177 证券简称：百奥泰 公告编号：2025-064 （一） 股东会召开的时间：2025 年 09 月 15 日 （二） 股东会召开的地点：广州市国际生物岛螺旋二路 18 号会议室 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 86 | | --- | --- | | 普通股股东人数 | 86 | | 2、出席会议的股东所持有的表决权数量 | 314,143,855 | | 普通股股东所持有表决权数量 | 314,143,855 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比例 | 75.8655 | | （%） | | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） | 75.8655 | （四） 表决方式是 ...

Investment Rating - The industry rating is "Positive" for the next 12 months, expecting a growth rate exceeding 10% relative to the CSI 300 index [67][79]. Core Insights - The report highlights the impressive research outcomes of Chinese pharmaceutical companies showcased at the 2025 World Lung Cancer Conference (WCLC), emphasizing the strength of innovation in the sector. It also notes that Heng Rui has further advanced its overseas licensing strategy through the NewCo model [9][67]. - The report suggests continuous monitoring of the R&D progress of Chinese pharmaceutical companies, particularly in innovative drugs and related industrial chains, benefiting from optimized procurement rules in the pharmaceutical and medical device sectors, as well as the recovery of traditional Chinese medicine and medical services due to domestic demand [9][67]. Industry News - Bai Li Tian Heng's dual-target ADC for EGFR/HER3 has shown promising results at WCLC, with a 100% overall response rate in a study involving 154 patients [18]. - BeiGene presented the latest findings from its RATIONALE studies at WCLC, demonstrating significant survival benefits for its drug in treating non-small cell lung cancer [19]. - Kangfang Biotech updated data from its HARMONi study, showing improved overall survival rates, particularly in North America [20]. Company Announcements - Heng Rui Pharma signed a licensing agreement with Braveheart Bio for the HRS-1893 project, with an upfront payment of $65 million and potential milestone payments totaling up to $1.013 billion [35]. - The new drug application for KN026 by CSPC has been accepted by the National Medical Products Administration (NMPA) [39]. - Junshi Biosciences reported positive results from its Phase III clinical trial for an anti-IL-17A monoclonal antibody [40]. Market Review - The Shanghai Composite Index rose by 2.91%, while the Shenzhen Component Index increased by 7.11%. The pharmaceutical and biological sector saw a 1.76% increase, with most sub-sectors showing positive performance [53][57]. - As of September 11, 2025, the TTM P/E ratio for the pharmaceutical and biological industry was 31.56, with a valuation premium of 148% relative to the CSI 300 [57]. Weekly Strategy - The report recommends focusing on investment opportunities in innovative drugs and medical devices, as well as sectors benefiting from domestic demand recovery, while maintaining a "Positive" industry rating [67].

Group 1 - Yishitong plans to repurchase shares worth between 30 million to 55 million yuan at a price not exceeding 40.69 yuan per share, intended for employee stock ownership plans or equity incentives [1] - Guoyao Modern's subsidiary has received approval for a sodium bicarbonate injection to increase specifications and pass consistency evaluation [2] - Xinjing plans to reduce its shareholding by up to 1.2 million shares, accounting for 0.78% of the total share capital, between October 14, 2025, and January 13, 2026 [2] Group 2 - Jinfeikeda intends to apply for an additional credit limit of up to 60 million yuan from Jiangsu Financial Leasing [3] - Boshi Co. signed a project contract worth 235 million yuan with Guoneng Yulin Chemical for a three-year service period starting from October 31, 2025 [4] - Luan Energy reported a coal sales volume of 3.78 million tons in August, a decrease of 13.70% year-on-year [6] Group 3 - Shengnong Development achieved sales revenue of 1.857 billion yuan in August, a year-on-year increase of 19.11% [8] - Huading Co. plans to transfer 9.26% of its shares through public solicitation of transferees [10] - China Metallurgical Group's new contract amount from January to August decreased by 18.2% year-on-year, totaling 679.57 billion yuan [12] Group 4 - Longjing Environmental plans to invest approximately 3.99 billion yuan in the construction of a hydropower station project in the Democratic Republic of the Congo [14] - Longjing Environmental also plans to invest 2.391 billion yuan in an integrated energy station project, expected to be operational by the second quarter of 2026 [15] - Transsion Holdings has set the transfer price for its shares at 81.81 yuan per share, with a subscription rate of 1.15 times [17] Group 5 - Sinopec Oilfield Services won a bid for a natural gas pipeline project with a contract value of 858 million yuan [18] - Huaitian Thermal Power received a warning letter from the Liaoning Securities Regulatory Bureau for information disclosure violations [20] - China Nuclear Engineering signed new contracts totaling 96.633 billion yuan as of August [22] Group 6 - Shanghai Mechanical plans to publicly transfer 67% of its stake in Simic Welding Materials, with an estimated value of 291 million yuan [24] - Zhongke Environmental appointed Tang Xia as the new deputy general manager [26] - Baiyang Pharmaceutical signed a strategic cooperation agreement with Jikun Pharmaceutical for a drug project [28] Group 7 - Jinsong New Materials received a warning letter from the Zhejiang Securities Regulatory Bureau for fundraising irregularities [27] - Weitang Industrial obtained a national invention patent for a battery tray welding deformation control device [29] - Dongsoft Carrier secured two national invention patents related to energy management and voltage regulation circuits [30] Group 8 - Lian De Equipment won a bid for the BOE AMOLED production line project with a total amount of 201 million yuan [31] - Jingjiawei signed a strategic cooperation agreement with Anchaoyun to develop high-performance cloud desktop solutions [32] - Chuaning Biological received approval for a 1 billion yuan medium-term note registration [34] Group 9 - Jifeng Co. plans to reduce its shareholding by up to 2% through block trading [36] - Taihe Intelligent plans to transfer 5.79% of its shares to Sunshine New Energy Development Co., Ltd. [36] - Yangmei Chemical will change its stock name to "Luhua Technology" starting September 17, 2025 [38] Group 10 - ST Songfa's subsidiary signed contracts for the construction of four container ships, with a total value of approximately 300 to 500 million USD [40] - Green Energy Huichong plans to establish a joint venture with Xianyang Economic Development Group with a registered capital of 250 million yuan [42] - Baiyao Tai received a milestone payment of 5.4 million USD from Intas Pharmaceuticals [38]

百奥泰生物制药股份有限公司 自愿披露关于与 Intas Pharmaceuticals Ltd.就 BAT2506（戈利木单抗）注射液签署授权许可与商 业化协议收到里程碑付款的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 公司于 2025 年 2 月 26 日召开 2025 年第一次临时股东大会，会议表决通过 了《关于就 BAT2506（戈利木单抗）签署授权许可与商业化协议的议案》，该协 议于当日起生效。 证券代码：688177 证券简称：百奥泰 公告编号：2025-062 百奥泰生物制药股份有限公司（以下简称"百奥泰"或"公司"）于北京时间 2025 年 2 月 10 日与 Intas Pharmaceuticals Ltd.（以下简称"Intas"）签署授权许可 与商业化协议，将公司的 BAT2506（戈利木单抗）注射液在美国市场的独占的产 品商业化权益有偿许可给 Intas（以下简称"协议"或"本协议"）。百奥泰将负责 研发、生产及商业化供应，Intas 将通过其美国子公司 Accord BioPharm ...

格隆汇9月11日｜百奥泰公告，公司于2025年2月26日召开2025年第一次临时股东大会，会议表决通过了 《关于就BAT2506(戈利木单抗)签署授权许可与商业化协议的议案》，该协议于当日起生效。根据协议 约定，公司于近日收到Intas支付的540.00万美元里程碑付款(已扣除60万美元为扣缴企业所得税，实际 到账金额需扣除银行手续费)，按照2025年9月11日中国人民银行公布的美元兑人民币中间价7.1034，共 计人民币3,835.84万元。截至本公告披露日，百奥泰BAT2506(戈利木单抗)注射液已向国家药品监督管 理局(NMPA)、美国食品药品监督管理局(FDA)、欧洲药品管理局(EMA)提交上市申请并获得受理。 来源：格隆汇APP ...

Core Insights - The company has signed a licensing and commercialization agreement with Intas Pharmaceuticals Ltd. for the exclusive commercialization rights of BAT2506 (Golimumab) injection in the U.S. market [1] - The company received a milestone payment of $5.4 million from Intas, after deducting $600,000 for corporate income tax, resulting in a net amount of approximately RMB 38.36 million [1] - This payment will enhance the company's cash reserves, supporting future pipeline research and internationalization strategies [1]

Group 1 - Dematech won a 900 million yuan overseas smart logistics project from a well-known e-commerce giant in Latin America, focusing on intelligent logistics cross-belt sorting systems and related services [1] - Kang En Bei received approval for the registration of short-term financing bonds and medium-term notes, with a total registration amount of 1 billion yuan, valid for two years [1][2] - Zhi Xiang Jin Tai's GR1803 injection for systemic lupus erythematosus clinical trial has been approved by the National Medical Products Administration [2] Group 2 - Jin Da Wei's subsidiary received approval for a veterinary drug product, pyridone, valid from September 3, 2025, to September 2, 2030 [4] - Fu Li Wang's subsidiary plans to invest 500 million yuan in a high-end wire material project, focusing on high-strength prestressed steel strands for various applications [5] - He Li Biological's subsidiary's Class III medical device registration application has been accepted, focusing on natural bone repair materials [12] Group 3 - Lin Yang Energy won a 244 million yuan metering equipment project from Southern Power Grid, expected to positively impact its 2025 and 2026 performance [20] - Sanxia Water plans to absorb its wholly-owned subsidiary, Chongqing Changdian United Energy, with all assets and liabilities to be inherited by Sanxia Water [13] - Tian Cheng Technology canceled the use of 91 million yuan of raised funds for permanent working capital, ensuring no impact on the normal operation of investment projects [24] Group 4 - Baosteel received approval to publicly issue bonds totaling 20 billion yuan to professional investors, valid for 24 months [52] - Tian Kang Biological reported a 10.15% year-on-year increase in pig sales in August, with a total of 263,800 pigs sold [53] - Xinjiang Construction won multiple major projects totaling 4.506 billion yuan, including a 2.4 billion yuan photovoltaic hydrogen synthesis project [18]

证券代码： 688177 证券简称： 百奥泰 公告编号：2025-061 百奥泰生物制药股份有限公司 自愿披露关于 Qletli®（阿达木单抗注射液）获得 英国 MHRA 上市批准的公告 现将相关情况公告如下： 一、 药品相关情况 （一） 药品名称：阿达木单抗注射液 （二） 商品名称：Qletli® （三） 剂型规格： 预充式注射器注射液：40mg/0.8mL （四） 成人适应症：类风湿关节炎、多关节型幼年特发性关节炎、与附着 点炎症相关的关节炎、强直性脊柱炎、无强直性脊柱炎影像学证据的中轴型脊 柱关节炎、银屑病关节炎、银屑病、化脓性汗腺炎、克罗恩病、溃疡性结肠炎、 葡萄膜炎；儿童适应症：多关节型幼年特发性关节炎、与附着点炎症相关的关 节炎、儿童斑块状银屑病、儿童克罗恩病、儿童溃疡性结肠炎、儿童葡萄膜炎 二、 药品其他相关情况 BAT1406 是百奥泰自主研发的阿达木单抗生物类似药，是由 CHO 细胞表 达的重组全人源单克隆抗体，通过与 TNF-α特异性结合并中和其生物学功能， 阻断其与细胞表面 TNF-α受体的相互作用，从而阻断 TNF-α的致炎作用。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载 ...

Core Viewpoint - Company Baiotai (688177.SH) has received marketing approval from the UK Medicines and Healthcare products Regulatory Agency (MHRA) for Qletli (BAT1406), a biosimilar of adalimumab, which is expected to enhance the company's international market presence and positively impact long-term operational performance [1] Group 1 - Qletli (BAT1406) is a fully human monoclonal antibody developed by the company, expressed in CHO cells, that specifically binds to and neutralizes TNF-α, blocking its inflammatory effects [1] - The approval allows the company to expand its product offerings in the UK market, thereby increasing its international influence [1] - The drug is indicated for various adult conditions including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, and ulcerative colitis, among others [1] Group 2 - Pediatric indications for Qletli include juvenile idiopathic arthritis, pediatric plaque psoriasis, and pediatric Crohn's disease [1] - The approval is expected to have a positive impact on the company's long-term business performance [1]